Group 1 - The core viewpoint of the articles highlights a positive trend in the medical device sector, with major stocks experiencing significant gains, indicating a recovery in the market [1] - The medical device index ETF (159898) showed a morning rebound with a rise of 1.03%, attracting over 15 million yuan in net subscriptions, reflecting investor confidence [2] - Future growth in the medical device industry is expected to be driven by technological advancements, AI diagnostics, and the expansion of consumer healthcare, transitioning to a higher development stage [2] Group 2 - Financial institutions like Caixin Securities maintain a "leading the market" rating for the medical device sector, anticipating high-quality development and long-term investment opportunities [2] - The impact of centralized procurement in high-cost areas is gradually diminishing, with some products benefiting from renewed contracts, suggesting a potential for volume and price increases in the coming years [2] - The medical device index ETF (159898) has seen a cumulative net value increase of 22.82% over the past year, outperforming its benchmark by 5.99%, ranking first among similar index ETFs [2][3]

Core Viewpoint - Jimin Health has experienced a significant stock price increase of 10.00%, achieving a price of 8.91 yuan and a total market capitalization of 4.679 billion yuan, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Strategic Collaborations - The company has entered into a strategic partnership with Dabo Bio in the field of cell gene therapy, focusing on the development of oncolytic virus drugs, which aligns with the biotechnology sector within the healthcare industry [1] - Jimin Health is participating in an AI entrepreneurship development fund, integrating AI with medical technology, thus tapping into the emerging trend of AI and healthcare convergence [1] Group 2: Market Confidence Initiatives - The company has announced a share repurchase plan worth 100-200 million yuan, aimed at strengthening market confidence and supporting the buyback concept [1] Group 3: Business Segments - Jimin Health is primarily involved in several key sectors including biotechnology, artificial intelligence, medical devices, medical services, and share buybacks, reflecting a diversified approach to growth and investment opportunities [1]

济民健康(603222)今日涨停，全天换手率17.99%，成交额7.42亿元，振幅11.88%。龙虎榜数据显示，营 业部席位合计净买入465.46万元。 上交所公开信息显示，当日该股因日涨幅偏离值达10.51%上榜，营业部席位合计净买入465.46万元。 融资融券数据显示，该股最新（8月13日）两融余额为1.62亿元，其中，融资余额为1.62亿元，融券余额 为5.81万元。近5日融资余额合计增加1299.80万元，增幅为8.74%。融券余额合计增加5.68万元，增幅 4156.52%。 4月29日公司发布的一季报数据显示，一季度公司共实现营业收入1.81亿元，同比下降22.49%，实现净 利润-1363.65万元。 7月12日公司发布上半年业绩预告，预计实现净利润-5500.00万元至-4600.00万元，同比变动区间 为-316.15%~-280.78%。（数据宝） 济民健康8月14日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 东方财富证券股份有限公司上海东方路证券营 ...

Core Viewpoint - The medical device sector experienced a decline of 2.16% on August 14, with Lide Man leading the drop, while the Shanghai Composite Index fell by 0.46% and the Shenzhen Component Index decreased by 0.87% [1]. Group 1: Market Performance - The medical device sector's overall performance was negative, with a notable decline in key stocks [1]. - Lide Man's stock price fell by 11.21%, closing at 10.06, with a trading volume of 1.06 million shares [2]. - The sector saw a net outflow of 1.517 billion yuan from major funds, while retail investors contributed a net inflow of 1.269 billion yuan [2]. Group 2: Top Gainers - Botao Biological (688767) saw a significant increase of 19.99%, closing at 45.13 with a trading volume of 104,300 shares and a transaction value of 436 million yuan [1]. - Toukeng Life (300642) rose by 10.85%, closing at 19.10 with a trading volume of 310,100 shares [1]. - Jimin Health (603222) increased by 10.05%, closing at 8.10 with a trading volume of 944,800 shares [1]. Group 3: Notable Decliners - Lide Man (300289) led the decline with a drop of 11.21%, closing at 10.06 with a trading volume of 1.0605 million shares [2]. - Zhonghong Medical (300981) fell by 9.91%, closing at 16.00 with a trading volume of 261,300 shares [2]. - Haitai New Light (688677) decreased by 7.93%, closing at 45.30 with a trading volume of 49,100 shares [2].

一、回购股份的基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 济民健康管理股份有限公司董事会 2025年8月1日 济民健康管理股份有限公司(以下简称"公司")于2025年3月28日召开第五届董事会第十七次会议，审议 通过了《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金及金融机构借款以集 中竞价交易方式回购公司股份，回购价格不超过人民币10元/股（含）；回购资金总额不低于人民币 10,000万元（含）且不超过人民币20,000万元（含）；回购期限为自董事会审议通过回购方案之日起不 超过12个月。具体内容详见公司于2025年3月29日在上海证券交易所网站披露的《公司关于 ...

Group 1 - The stock price of Jimin Health is reported at 6.92 yuan, down 0.15 yuan from the previous trading day, representing a decline of 2.12% [1] - The trading volume for the day was 89,780 hands, with a transaction amount of 0.63 million yuan [1] - Jimin Health operates in the pharmaceutical manufacturing industry, with its main business segments including pharmaceutical manufacturing, medical services, and pharmaceutical trade [1] Group 2 - According to the 2024 annual report, the pharmaceutical manufacturing business accounts for 55.95% of total revenue, while medical services contribute 41.43% [1] - As of July 31, the company has repurchased 2.01 million shares, representing 0.38% of the total share capital, with a repurchase amount of 12.09 million yuan [1] - In the first quarter of 2025, the company reported revenue of 181 million yuan, with a net profit loss of 13.64 million yuan [1] Group 3 - Data shows that on July 31, Jimin Health experienced a net outflow of main funds amounting to 16.57 million yuan, which is 0.46% of the circulating market value [1]

证券日报网讯7月31日晚间，济民健康（603222）发布公告称，2025年7月份，公司未实施回购。截至 2025年7月31日，公司通过集中竞价交易方式累计回购股份2，005，500股，占公司总股本的比例为 0.3819%。 ...

Group 1 - The core point of the article is that Jimin Health has announced a share buyback program, repurchasing approximately 2.01 million shares, which accounts for 0.3819% of the total share capital, with a total expenditure of about 12.09 million yuan [2] Group 2 - As of July 31, 2025, the company has conducted the share buyback through centralized bidding, with the highest purchase price being 6.13 yuan per share and the lowest at 5.87 yuan per share [2] - For the fiscal year 2024, the revenue composition of Jimin Health is as follows: pharmaceutical manufacturing accounts for 55.95%, medical services for 41.43%, pharmaceutical trading for 1.75%, and other businesses for 0.87% [2]

| 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 200.55万股 | | 累计已回购股数占总股本比例 | 0.38% | | 累计已回购金额 | 1,208.90万元 | | 实际回购价格区间 | 5.87元/股~6.13元/股 | 一、回购股份的基本情况 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融机构借款以集中竞价交易方式回购公司股 份，回购价格不超过人民币 10 元/股（含）；回购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）；回购期限为自董事会审议通过回 购方案之日起不超过 12 个月。具体内容详见公司于 20 ...

格隆汇7月31日丨济民健康（维权）(603222.SH)公布，2025年7月，公司未实施回购。截止2025年7月31 日，公司通过集中竞价交易方式累计回购股份2,005,500股，占公司总股本的比例为0.3819%，购买的最 高价为6.13元/股，最低价为5.87元/股，已支付的总金额为12,088,967.50元（不含交易费用）。上述回购 符合相关法律法规的规定及公司既定的回购股份方案。 ...